Apogee Therapeutics (APGE) Current Leases (2023 - 2026)

Apogee Therapeutics (APGE) has reported Current Leases for 4 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 22.5% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 22.5% YoY), while the FY2025 annual figure was $3.5 million, up 8.35% from the prior year.
• Current Leases fell to $3.1 million in Q1 2026 per APGE's latest filing, from $3.5 million in the prior quarter.
• Across five years, Current Leases topped out at $4.1 million in Q3 2025 and bottomed at $1.1 million in Q4 2023.
• Historically, Current Leases has averaged $2.9 million across 4 years, with a median of $3.2 million in 2024.
• Annual changes were most pronounced in 2025 — Current Leases jumped 250.57% — and 2026, when it slipped 22.5%.
• Apogee Therapeutics' Current Leases stood at $1.1 million in 2023, then jumped by 193.73% to $3.2 million in 2024, then grew by 8.35% to $3.5 million in 2025, then declined by 11.53% to $3.1 million in 2026.
• Business Quant data shows APGE's Current Leases at $3.1 million in Q1 2026, $3.5 million in Q4 2025, and $4.1 million in Q3 2025.